These genes were selected because: (1) of their overexpression in HCC patients (SCN8A in 41%, ACTN1 in 22%, SRD5A2 in 5%, NFkB2 in 56%, NEURL1B in 46%); (2) of their action as oncogenes in cancer cells (and particularly in HCC) has been less explored in previous studies (with the exception of NFkB2 and SRD5A). This evidence concerns the gene NEURL1B and cancer.